Insulet Corporation

Robbins Arroyo LLP Reminds Shareholders of Insulet Corporation (PODD) that the Company Misled Shareholders According to a Recently Filed Class Action

According to a federal securities fraud class action complaint filed in the U.S. District Court for the District of Massachusetts, officers and directors of Insulet Corporation (NASDAQGS: PODD) violated the Securities Exchange Act of 1934 between February 27, 2013 and April 30, 2015, by making materially false and misleading statements about their business prospects.

Insulet Misrepresents Its Business Practices

According to the complaint, defendants misrepresented the success of the rollout of Insulet’s new insulin infusion system known as OmniPod Eros, manipulated the way the company reported the number of new patients using OmniPod Eros, and inflated international sales to conceal the company’s declining growth. When the truth was revealed on April 30, 2015, shares of Insulet declined nearly 10% to close at $26.97 on May 1, 2015.

Insulet Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Address City State/Province *
ZIP/Postal Code Country/Region Phone *
E-mail * Confirm: E-mail *

Shares Purchased:
Number of Shares: Buy Date : Price Per Share:
example: 125 example: MM/DD/YYYY example: 30.00
transaction:
transaction:
transaction:
transaction:
transaction:
If you have additional transactions or comments, please input the information below:

Shares Sold:
Number of Shares: Sell Date : Price Per Share:
example: 125 example: MM/DD/YYYY example: 30.00
transaction:
transaction:
transaction:
transaction:
transaction:
If you have additional transactions or comments, please input the information below:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post

    Tags: